New diabetes clinical trial: The Objective is to Evaluate and Compare the Weight Loss in Patients With DM2 Treated With the Different aGLP1 for the First Time. Secondary Endpoints Are HbA1c Reduction, Changes in Quality of Life and Physical Activity and the Safety of These Drugs.

Published on: November 29, 2021 at 10:30PM
Conditions:   Weight Loss;   Diabetes Mellitus, Type 2;   Quality of Life;   Safety Issues
Intervention:   Drug: GLP-1 receptor agonist
Sponsor:   Jose Seijas Amigo
Not yet recruiting
https://ift.tt/31d1P68